G12V and G12A KRAS mutations are associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab
The DOI matches its Crossref record; 43 of the 44 references it cites were found in a registry or an index.
Abstract
The v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations are found in 35-45 % of colorectal cancer (CRC) cases. Although the association between the RAS signaling and angiogenesis is well known, the negative predictive value of KRAS mutation has not been established in patients treated with bevacizumab. The aim of this study was to evaluate the association between specific KRAS mutation types and outcome of patients with metastatic CRC treated with bevacizumab. The study included 404 patients with metastatic CRC (mCRC) treated with bevacizumab. Clinical data obtained from the clinical registry CORECT were retrospectively analyzed. The shortest survival was observed in patients with tumors harboring G12V or G12A KRAS mutation (G12V/A). The median progression-free survival (PFS) and overall survival (OS) for patients with tumors harboring G12V/A KRAS mutation was 6.6 and 16.8 compared to 11.6 and 26.3 months for patients with tumors harboring other KRAS mutation type (p < 0.001 and p < 0.001), while the survival of patients harboring other KRAS mutation types was comparable to those with tumors harboring wild-type KRAS gene. In the Cox multivariable analysis, KRAS G12V/A mutation type remains a significant factor predicting both PFS (HR = 2.18, p < 0.001) and OS (HR = 2.58, p < 0.001). In conclusion, the results of the present study indicate that there is a significant difference in biological behavior between tumors harboring G12V/A and other KRAS mutations. M…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Given the fact that KRAS mutations are often associated with poor prognosis in CRC patients [4]”
From Genome-wide CRISPR-cas9 knockout screening identifies GRB7 as a driver for MEK inhibitor resistance in KRAS mutant colon cancer (2022) · cites this paper as [4]
In the citing paper
“The median PFS was 10.6 (95% CI: 6.8, 14.3) months in patients with KRAS G12C, while the median PFS ranged from 3.5 to 15.1 months with other KRASm.”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [55]
In the citing paper
“In this study, the PFS and OS of patients with KRAS G12C tumors were comparable to those with other KRASm tumors (with the exception of KRAS G12V and KRAS G12A tumors which were associated with significantly shorter survival outcomes) and to those with KRASwt tumors.”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [55]
In the citing paper
“In a retrospective analysis of data from 404 patients with mCRC who were treated with bevacizumab (80% received bevacizumab as first-line treatment), the median OS in patients with KRAS G12C was shorter (27.4 [95% CI: 10.0, 44.8] months) than in patients with KRAS G12D (28.7 months) and KRAS G12S (32.7 months), but longer than in those with KRAS G12A, KRAS G12V, and KRAS G13D (range, 16.1 to 22.8”
From Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review (2023) · cites this paper as [55]
In the citing paper
“KRAS mutations are often associated with resistance to targeted therapies and poor outcomes in patients with cancer”
From KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors (2020) · cites this paper as [4]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Watnick, R. S., Cheng, Y.-N., Rangarajan, A., Ince, T. A., & Weinberg, R. A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00030-8 · Cited by 318
RetractedJemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229
RAS oncogenes: the first 30 years
Malumbres, M., & Barbacid, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1097 · Cited by 1,902
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Essential role for oncogenic Ras in tumour maintenance
Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O'Hagan, R., Pantginis, J., Zhou, H., et al. (1999) · Nature · doi:10.1038/22788 · Cited by 875
Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study
Andreyev, H. J. N., Norman, A. R., Cunningham, D., Oates, J., Dix, B. R., Iacopetta, B. J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1964 · Cited by 872
Hecht, J. R., Mitchell, E., Chidiac, T., Scroggin, C., Hagenstad, C., Spigel, D., Marshall, J., Cohn, A., McCollum, D., Stella, P., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.8135 · Cited by 850
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830
Rak, J. W., Mitsuhashi, Y., Bayko, L., Filmus, J., Shirasawa, S., Sasazuki, T., & Kerbel, R. S. (1995) · PubMed · Cited by 762
Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study
Andreyev, H. J. N., Norman, A. R., Clarke, P. A., Cunningham, D., & Oates, J. R. (1998) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/90.9.675 · Cited by 748 · cited 1×
“Several experimental studies have shown that G12V KRAS mutation possesses increased oncogenic potential and is associated with more aggressive cancer behavior compared to G12D KRAS mutation [10, 35, 36].”
BackgroundKabbinavar, F. F., Hambleton, J., Mass, R. D., Hurwitz, H. I., Bergsland, E., & Sarkar, S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.232 · Cited by 686
Van Cutsem, E., Rivera, F., Berry, S., Kretzschmar, A., Michael, M., DiBartolomeo, M., Mazier, M.-A., Canon, J.-L., Georgoulias, V., Peeters, M., et al. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp233 · Cited by 532
(1996) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60862-3 · Cited by 510 · cited 1×
“Although it has been reported that various pro-angiogenic growth factors such as VEGF, TGF-alpha, or TGF-beta can be induced or strongly upregulated by mutant RAS oncogenes, the relevance of KRAS mutation status in the efficacy of antiangiogenic agents remains unclear [22, 23].”
BackgroundClinical Relevance of KRAS in Human Cancers
Jančík, S., Drábek, J., Radzioch, D., & Hajdúch, M. (2010) · Journal of Biomedicine and Biotechnology · doi:10.1155/2010/150960 · Cited by 402 · cited 1×
“KRAS gene mutations can compromise the intrinsic GTPase activity, resulting in constitutively active KRAS protein that triggers various downstream effector signaling pathways [15, 16].”
BackgroundFrequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Pathology - Research and Practice · doi:10.1016/j.prp.2009.07.010 · Cited by 361
Ahnen, D. J., Feigl, P., Quan, G., Fenoglio‐Preiser, C. M., Lovato, L., Bunn, P. A., Stemmerman, G. N., Wells, J. D., Macdonald, J. S., & Meyskens, F. L. (1998) · PubMed · Cited by 338
Forbes, S., Clements, J., Dawson, E., Bamford, S., Webb, T., Dogan, A., Flanagan, A., Teague, J., Wooster, R., Futreal, P. A., et al. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602928 · Cited by 331
Association of k-ras, b-raf, and p53 Status With the Treatment Effect of Bevacizumab
Ince, W. L., Jubb, A. M., Holden, S. N., Holmgren, E. B., Tobin, P., Sridhar, M., Hurwitz, H. I., Kabbinavar, F., Novotny, W. F., Hillan, K. J., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji174 · Cited by 319
K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study
Brink, M. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg009 · Cited by 315
Kozloff, M., Yood, M. U., Berlin, J., Flynn, P. J., Kabbinavar, F. F., Purdie, D. M., Ashby, M. A., Dong, W., Sugrue, M. M., Grothey, A., et al. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0071 · Cited by 305
Rak, J. W., Mitsuhashi, Y., Sheehan, C., Tamir, A., Viloria‐Petit, A., Filmus, J., Mansour, S. J., Ahn, N. G., & Kerbel, R. S. (2000) · PubMed · Cited by 288
Hurwitz, H. I., Yi, J., Ince, W., Novotny, W. F., & Rosen, O. (2009) · The Oncologist · doi:10.1634/theoncologist.2008-0213 · Cited by 239
Oncogenes as inducers of tumor angiogenesis
Rak, J., Filmus, J., Finkenzeller, G., Grugel, S., Marm�, D., & Kerbel, R. S. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690598 · Cited by 235 · cited 1×
“Although it has been reported that various pro-angiogenic growth factors such as VEGF, TGF-alpha, or TGF-beta can be induced or strongly upregulated by mutant RAS oncogenes, the relevance of KRAS mutation status in the efficacy of antiangiogenic agents remains unclear [22, 23].”
BackgroundK-ras and p16 Aberrations Confer Poor Prognosis in Human Colorectal Cancer
Esteller, M., González, S., Risques, R. A., Marcuello, E., Mangues, R., Germà, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.2.299 · Cited by 234
Price, T. J., Hardingham, J. E., Lee, C. K., Weickhardt, A., Townsend, A. R., Wrin, J. W., Chua, A., Shivasami, A., Cummins, M. M., Murone, C., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5520 · Cited by 209
Al-Mulla, F., Going, J. J., Sowden, E. T. H. H., Winter, A., Pickford, I. R., & Birnie, G. D. (1998) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199806)185:2<130::aid-path85>3.0.co;2-m · Cited by 123
Al-Mulla, F., Milner-White, E. J., Going, J. J., & Birnie, G. D. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199903)187:4<433::aid-path273>3.0.co;2-e · Cited by 110 · cited 1×
“The GTPase activity of G12V-mutatedKRAS protein was found to be only one quarter of the activity of G12D-mutated KRAS protein and one tenth of wild-type KRAS protein activity [37].”
BackgroundFrequency and Type of KRAS Mutations in Routine Diagnostic Analysis of Metastatic Colorectal Cancer
Neumann, J., Zeindl-Eberhart, E., Kirchner, T., & Jung, A. (2009) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0029-1242277 · Cited by 97
Cespedes, M. V., Sancho, F. J., Guerrero, S., Parreno, M., Casanova, I., Pavon, M. A., Marcuello, E., Trias, M., Cascante, M., Capella, G., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl063 · Cited by 67 · cited 2×
“Several experimental studies have shown that G12V KRAS mutation possesses increased oncogenic potential and is associated with more aggressive cancer behavior compared to G12D KRAS mutation [10, 35, 36].”
BackgroundPetrelli, F., Coinu, A., Cabiddu, M., Ghilardi, M., & Barni, S. (2013) · Medical Oncology · doi:10.1007/s12032-013-0650-4 · Cited by 56 · cited 1×
“reported longer PFS and OS for patients with tumors exhibiting wild-type KRAS gene compared to patients with tumors harboring KRAS mutation [24, 25].”
BackgroundWinder (2009) · Oncology Reports · doi:10.3892/or_00000352 · Cited by 51
Díaz‐Rubio, E., Gómez‐España, A., Massutí, B., Sastre, J., Reboredo, M., Manzano, J. L., Rivera, F., Safont7, M., Montagut, C. O., González‐Flores, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047345 · Cited by 43 · cited 1×
“reported longer PFS and OS for patients with tumors exhibiting wild-type KRAS gene compared to patients with tumors harboring KRAS mutation [24, 25].”
BackgroundBruera, G., Cannita, K., Giacomo, D. D., Lamy, A., Frébourg, T., Sabourin, J. C., Tosi, M., Alesse, E., Ficorella, C., & Ricevuto, E. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-59 · Cited by 25 · cited 1×
“FOx) plus bevacizumab, although the cohort was small, including only 59 patients (27 patients with KRAS mutation) [30].”
BackgroundBencsikova, B., Bortlicek, Z., Halamkova, J., Ostrizkova, L., Kiss, I., Melichar, B., Pavlik, T., Dusek, L., Valik, D., Vyzula, R., et al. (2015) · BMC Gastroenterology · doi:10.1186/s12876-015-0266-6 · Cited by 21 · cited 2×
“Outcome of part of the same cohort have been recently published in a report that covered all centers in the country but did not include details of KRAS mutational status [13].”
BackgroundResultSelf-citationAssociation of K-ras codon 12 transversions with short survival in non-small cell lung cancer
Vega, F., Iniesta, P., Caldés, T., Sánchez, A., Lopez, J., de Juan, C., Díaz‐Rubio, E., Torres, A., Balibrea, J., & Benito, M. (1996) · International Journal of Oncology · doi:10.3892/ijo.9.6.1307 · Cited by 14 · cited 1×
“Several experimental studies have shown that G12V KRAS mutation possesses increased oncogenic potential and is associated with more aggressive cancer behavior compared to G12D KRAS mutation [10, 35, 36].”
BackgroundMizutani, N., Ito, H., Hagiwara, K., Kobayashi, M., Hoshikawa, A., Nishida, Y., Takagi, A., Kojima, T., Suzuki, M., Osawa, Y., et al. (2012) · PubMed Central · doi:10.18999/nagjms.74.3-4.261 · Cited by 9 · cited 1×
“has reported that G12A-mutatedKRAS protein also interacts primarily with RAF through the ERK signaling pathway [38].”
Background
Cited by
KRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
A Comparative Analysis of Individual RAS Mutations in Cancer Biology
Muñoz-Maldonado, C., Zimmer, Y., & Medová, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01088 · Cited by 254
“Patients carrying mutant variants at codons 12 or 13 had shorter OS and PFS than those with WT KRAS (72).”
BackgroundSerebriiskii, I. G., Connelly, C., Frampton, G., Newberg, J., Cooke, M., Miller, V., Ali, S., Ross, J. S., Handorf, E., Arora, S., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11530-0 · Cited by 215
de Miguel‐Pérez, D., Martínez, A. R., Palomo, A. O., Ureña, M. D., Puche, J. L. G., Robles-Remacho, A., Hernández, J. E., Lorente, J. A., Ortega, F. G., & Serrano, M. J. (2020) · Scientific Reports · doi:10.1038/s41598-020-60212-1 · Cited by 133
Current therapy of KRAS-mutant lung cancer
Ghimessy, A., Radeczky, P., Laszlo, V., Hegedus, B., Renyi-Vamos, F., Fillinger, J., Klepetko, W., Lang, C., Dome, B., & Megyesfalvi, Z. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09903-9 · Cited by 115
“Only two groups reported that G12V, G12A [54], and G12D [55] KRAS mutations are associated with poor outcome in patients with colorectal cancer (CRC) receiving bevacizumab.”
Background
Metadata
- Authors
- Fiala, O., Buchler, T., Mohelnikova-Duchonova, B., Melichar, B., Matejka, V. M., Holubec, L., Kulhankova, J., Bortlicek, Z., Bartouskova, M., Liska, V., Topolcan, O., Sedivcova, M., & Finek, J.
- Affiliations
- Palacký University Olomouc (CZ)
- Charles University (CZ)
- Venue
- Tumor Biology
- Published
- 2015-12-10
- Volume
- 37
- Issue
- 5
- Pages
- 6823-6830
- ISSN
- 1010-4283 (ISSN-L)
- 1423-0380
- OpenAlex
- W2464728687
- Cited by
- 55
- References
- 44
- Citations by year
- 2026: 1 · 2025: 8 · 2024: 3 · 2023: 8 · 2022: 3 · 2021: 6 · 2020: 7 · 2019: 10 · 2018: 4 · 2017: 4 · 2016: 1
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Tumor Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Ministry of Education Youth and Sports of the Czech Republic (LO1503)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- KRAS mutation, metastatic colorectal cancer, bevacizumab, prognostic factors, progression-free survival, overall survival, Ras signaling, angiogenesis
- MeSH terms
- Bevacizumab, Adult, Aged, Aged, 80 and over, Alleles, Codon, Combined Modality Therapy, Female, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Prognosis, Colorectal Neoplasms, Proportional Hazards Models, Treatment Outcome, ras Proteins, Retreatment, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.